Company that claims to be paving a new path from genes to therapeutic proteins using its messenger RNA technology platform
Ethris has raised €60M across 4 funding rounds from 4 investors, most recently a round in Sep 2026. Based in Bayern, Germany; active in Healthtech. Data as of 21 Sept 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-09-11 | Other | €30M | European Investment Bank (EIB) | View deal → |
| 2025-05-09 | Grant | €10M | EU4Health Grant | View deal → |
| 2024-06-18 | Other | €4.7M | The Bill & Melinda Gates Foundation | View deal → |
| 2023-01-03 | Other | €15M | Cipla EU | View deal → |
